期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

乳腺癌患者的妇产科问题与康复治疗策略 被引量：1

原文传递
导出
摘要 本文在解读美国妇产科医师临床实践指南“乳腺癌患者的妇产科问题与处理2012年版”_l0的基础上，对乳腺癌患者的妇产科问题与康复治疗策略进行了讨论，希望为乳腺癌诊疗与康复多学科团队合作提供帮助。
作者 徐青 李青 远丽 岳军忠 于飞
机构地区 首都医科大学康复医学院普通外科学系 航空总医院妇产科
出处 《国际外科学杂志》 2014年第3期165-168,共4页 International Journal of Surgery
关键词 乳腺癌患者 妇产科医师 康复治疗 临床实践指南 团队合作
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献18

  • 1Practice Bulletin:clinical management guidelines for obstetriciangynecologists.Management of Gynecologic Issues in Women With Breast Cancer[J].Obstetrics & Gynecology,2012,119 (3):666-682.
  • 2Rosendahl M,Andersen CY,la Cour Freiesleben N,et al.Dynamics and mechanisms of chemotherapy-induced ovarian follicular depletion in women of fertile age[J].Fertil Steril,2010,94 (1):156-166.
  • 3Domchek SM,Friebel TM,Singer CF,et al.Association of riskreducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality[J].JAMA,2010,304(9):967-975.
  • 4徐青,远丽,李青,石青青.乳腺癌康复治疗现状与进展[J].中国康复理论与实践,2014,20(2):101-104. 被引量：22
  • 5Cuzick J,Powles T,Veronesi U,et al.Overview of the main outcomes in breast-cancer prevention trials[J].Lancet,2003,361(9345):296-300.
  • 6Loprinzi CL,Zahasky KM,Sloan JA,et al.Tamoxifen-induced hot flashes[J].Clin Breast Cancer,2000,1 (1):52-56.
  • 7Janni W,Hepp P.Adjuvant aromatase inhibitor therapy:outcomes and safety[J].Cancer Treat Rev,2010,36(3):249-261.
  • 8应用芳香化酶抑制剂的绝经后乳腺癌患者骨丢失和骨质疏松的预防诊断和处理共识[J].中华肿瘤杂志,2013,35(11):876-879. 被引量：14
  • 9Brennan ME,Houssami N.Overview of long term care of breast cancer survivors[J].Maturitas,2011,69 (2):106-112.
  • 10Rostock M,Fischer J,Mumm A,et al.Black cohosh (Cimicifuga racemosa) in tamoxifen-treated breast cancer patients with climacteric complaints-a prospective observational study[J].Gynecol Endocrinol,2011,27(10):844-848.

二级参考文献71

  • 1徐根强,冀会学,吕峰.乳腺癌术后患侧上肢淋巴水肿原因及防治探讨[J].现代肿瘤医学,2006,14(7):825-826. 被引量：43
  • 2唐旭,赵斌,谢杰荣.青年乳腺癌患者术后性生活质量变化及其影响因素调查[J].神经疾病与精神卫生,2006,6(3):185-187. 被引量：15
  • 3Lipton A, Smith MR, Ellis GK, et al. Treatment-induced bone loss and fractures in cancer patients undergoing hormone ablation therapy: efficacy and safety of denosumab. Clin Med Insights Oncol, 2012, 6:287-303.
  • 4Chen Z, Maricic M, Pettinger M, et al. Osteoporosis and rate of bone loss among postmenopansal survivors of breast cancer. Cancer, 2005, 104:1520-1530.
  • 5Chen Z, Maricic M, Aragaki AK, et al. Fracture risk increases after diagnosis of breast or other cancers in postmenopausal women : results from the Women's Health Initiative. Osteoporos Int, 2009, 20:527-536.
  • 6.o Hadji P, Body JJ, Aapro MS, et al. Practical guidance for the management of arematase inhibitor-associated bone loss. Ann Oncol, 2008, 19:1407-1416.
  • 7Lastberg MB, Reinbolt RE, Shapiro CL. Bone health in adult cancer survivorship. J Clin Oncol, 2012, 30:3665-3674.
  • 8Watts NB, Bilezikian JP, Camacho PM, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract, 2010, 16(Suppl 3) :1-37.
  • 9Guise TA. Bone loss and fracture risk associated with cancer therapy. Oncologist, 2006, 11:1121-1131.
  • 10Eastell R, Adams JE, Coleman RE, et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol, 2008, 26 : 1051-1057.

共引文献34

同被引文献3

引证文献1

二级引证文献2

国际外科学杂志
2014年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部